Key result
Pediatric familial Mediterranean fever patients with subclinical inflammation had a significantly higher likelihood of presenting with erysipelas-like erythema compared to those without subclinical inflammation (21.7% vs 2.9%; OR 9.17).
Why the study?
Erysipelas-like erythema is not frequently seen in pediatric familial Mediterranean fever, and its relationship with disease characteristics and subclinical inflammation required evaluation.
Is erysipelas-like erythema associated with a more severe disease phenotype and subclinical inflammation in pediatric patients with familial Mediterranean fever?
Observational (n=515)
No
Is erysipelas-like erythema associated with a more severe disease phenotype and subclinical inflammation in pediatric patients with familial Mediterranean fever?
Odds Ratio: 9.17 (95% CI 4.39–19.16)
Absolute Event Rate: 21.7% vs 2.9%
p-value: p=<0.001
Erysipelas-like erythema in pediatric familial Mediterranean fever is associated with a more severe disease course and subclinical inflammation.
OBJECTIVE: Erysipelas-like erythema is the pathognomonic skin manifestation of familial Mediterranean fever although not frequently seen in the pediatric population. This study aims to describe the differences between patients presenting with and without erysipelas-like erythema and to examine the relation of erysipelas-like erythema with subclinical inflammation in a large pediatric cohort of familial Mediterranean fever patients. MATERIALS AND METHODS: This retrospective study from a single pediatric rheumatology referral center included familial Mediterranean fever patients with a follow-up for at least 6 months in the last 5 years. Patients were grouped according to the presence of erysipelas-like erythema and subclinical inflammation. RESULTS: Among 515 patients with familial Mediterranean fever, 35 patients (6.8%) were found to present with erysipelas-like erythema, and the earliest age for erysipelas-like erythema was 2.9 years. All erysipelas-like erythema lesions were defined on lower extremities with concurrent arthritis in 21 patients (60.0%). Compared to other patients in the cohort, patients presented with erysipelas-like erythema had significantly higher frequencies of acute arthritis, subclinical inflammation, and biallelic exon 10 mutations, and they used significantly higher doses of colchicine at the latest visits (all P ≤ .002). Patients with subclinical inflammation more frequently presented with erysipelas-like erythema compared to others without subclinical inflammation (21.7% vs. 2.9%, P < .001). CONCLUSION: Erysipelas-like erythema is an uncommon but important finding that can be a sign of severe disease course and subclinical inflammation in the pediatric population with familial Mediterranean fever.
No takes yet. Share an insight, caveat, or question.
Avar-Aydın et al. (2022) conducted an observational in Familial Mediterranean Fever (n=515). Subclinical inflammation vs. No subclinical inflammation was evaluated on Presentation with erysipelas-like erythema (ELE) (OR 9.17, 95% CI 4.39-19.16, p=<0.001). Pediatric familial Mediterranean fever patients with subclinical inflammation had a significantly higher likelihood of presenting with erysipelas-like erythema compared to those without subclinical inflammation (21.7% vs 2.9%; OR 9.17).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: